Zolazepam hydrochloride
CAS: 33754-49-3
Ref. 3D-FZ61533
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar | ||
| 50mg | A consultar |
Informação sobre produto
- 4-(2-fluorophenyl)-1,3,8-trimethyl-6,8-dihydropyrazolo[3,4-e][1,4]diazepin-7(1H)-one hydrochloride (1:1)
- 4-(o-Fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo(3,4-e)(1,4)diazepin-7(1H)-one monohydrochloride
- Ci 716
- Pyrazolo(3,4-e)(1,4)diazepin-7(1H)-one, 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethyl-, monohydrochloride
- Pyrazolo[3,4-e][1,4]diazepin-7(1H)-one, 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethyl-, hydrochloride (1:1)
- Telazol
- Unii-45Sj093Q1N
- Zolazepam HCl
- Zolazepam hydrochloride [USAN]
- 4-(2-Fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo(3,4-e)(1,4)diazepin-7(1H)-one monohydrochloride
- Ver mais sinónimos
Zolazepam is a benzodiazepine that has antinociceptive properties and is used as an anesthetic. The effective dose of zolazepam in humans is 5-10 mg intravenously, with a maximum dose of 25 mg. Zolazepam has been found to have no effect on systolic blood pressure or heart rate, but does cause significant reduction in terminal half-life. Zolazepam's antinociceptive effects are mediated through the inhibition of calcium ion channels, which results in decreased neuronal activity in the spinal cord and brainstem. Zolazepam causes sedation and immobilization by suppressing the function of neurons that control skeletal muscles.
Zolazepam also has been shown to inhibit osteoclast formation, which may be beneficial for patients with metabolic bone diseases such as Paget's disease or osteoporosis.
Propriedades químicas
Consulta técnica sobre: 3D-FZ61533 Zolazepam hydrochloride
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
